Session Details

While clinical trials are a required part of the drug research and development process, interventional clinical trials for rare diseases often have suboptimal designs due to recruitment limitations, insufficient representation of patient populations, and inadequate endpoints. Moreover, funding considerations that can impact the clinical development of various investigational therapies. However, many groups and organizations have developed innovative strategies for patient recruitment by making organized efforts to work directly with the various communities, cultures, and stakeholders a new treatment may affect. This workshop will share proven practices of optimizing CT enrollment, trial designs, and endpoints, as well as funding management when trials may unexpectedly end.